TEE
UBX

Tibra Equities Europe’s Unity Biotechnology UBX Stock Holding History

Tibra Equities Europe’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,070
Closed -$374K – 183
2021
Q2 		$374K Buy
+8,070
New +$389K 0.12% 40

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Tibra Equities Europe's UBX Position: Q3 2021 in Review

Tibra Equities Europe sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 8,070 shares — an estimated $374K sold.

Tibra Equities Europe first reported a position in UBX in Q2 2021 and held it in 1 quarter. The position peaked at $374K in Q2 2021. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

  • Tibra Equities Europe reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 8,070 Unity Biotechnology shares in Q3 2021, an estimated $374K.
  • Tibra Equities Europe first reported a position in Unity Biotechnology in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Unity Biotechnology position peaked at $374K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.